Carfilzomib Administered Once Weekly Prolongs PFS in Multiple Myeloma

Share this content:
Patients with R/R MM receiving carfilzomib once weekly had a significantly superior PFS over those receiving it twice weekly.
Patients with R/R MM receiving carfilzomib once weekly had a significantly superior PFS over those receiving it twice weekly.

A higher dose of carfilzomib administered once weekly prolonged progression-free survival (PFS) among patients with relapsed or refractory (R/R) multiple myeloma (MM) by 3.6 months compared with twice-weekly administration of a lower dose, according to results from an interim analysis noted in a press release.1

In the phase 3 ARROW study (ClinicalTrials.gov Identifier: NCT02412878), researchers randomly assigned 478 patients with R/R MM to receive carfilzomib 70 mg/m2 once weekly plus dexamethasone or carfilzomib 27 mg/m2 twice weekly plus dexamethasone. Study patients must have received at least 2, but no more than 3, prior treatments, including bortezomib and an immunomodulatory agent.

The primary outcome of the study is PFS; secondary outcomes include overall response rate, overall survival, safety, and tolerability.

Patients receiving carfilzomib once weekly had a significantly superior PFS of 11.2 months vs 7.6 months for patients receiving the drug twice weekly (hazard ratio [HR], 0.69; 95% CI, 0.54-0.88).

The treatment arms had comparable safety profiles. The most frequently reported adverse events included anemia, diarrhea, fatigue, insomnia, hypertension, and pyrexia.

MM is an incurable hematologic cancer defined as the formation of malignant plasma cells in the bone marrow. The disease is characterized by a recurring pattern of remission and relapse. MM accounts for 0.7% of all diagnosed cancers and approximately 13,000 deaths annually in the US.

Reference

  1. Phase 3 A.R.R.O.W. study of once-weekly Kyprolis (carfilzomib) regimen meets primary endpoint of progression-free survival in relapsed and refractory multiple myeloma patients [news release]. Thousand Oaks, CA: PRNewswire; October 23, 2017. https://www.prnewswire.com/news-releases/phase-3-arrow-study-of-once-weekly-kyprolis-carfilzomib-regimen-meets-primary-endpoint-of-progression-free-survival-in-relapsed-and-refractory-multiple-myeloma-patients-300541392.html. Accessed October 24, 2017.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs